Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
US-2017190688-A1 · Jul 6, 2017 · US
PRMT5 inhibitors
US11098059B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11098059-B2 |
| Application number | US-201816762114-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 5, 2018 |
| Priority date | Nov 8, 2017 |
| Publication date | Aug 24, 2021 |
| Grant date | Aug 24, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from one of the following, or a pharmaceutically acceptable salt thereof. 2. A composition for treating cancer comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 3. A method for treating cancer comprising administering to a patient in need thereof a composition of claim 2 .
Assignees
Inventors
Classifications
containing isoquinuclidine ring systems · CPC title
containing three or more hetero rings · CPC title
- C07D498/08Primary
Bridged systems · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11098059B2 cover?
- The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
- Who is the assignee on this patent?
- Merck Sharp & Dohme
- What technology area does this patent fall under?
- Primary CPC classification C07D498/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).